Diabetes in the United States. [cited 2020 Nov 1]. Available from: https://www.cdc.gov/diabetes/pdfs/library/socialmedia/diabetes-infographic.pdf.

Management of the diabetic patient with advanced chronic kidney disease.

Semin Dial. 23: 140-147Zelnick LR Weiss NS Kestenbaum BR et al.

Diabetes and CKD in the United States population, 2009-2014.

Clin J Am Soc Nephrol. 12: 1984-1990Go AS Yang J Tan TC et al.

Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.

BMC Nephrol. 19: 146United States Renal Data System

2020 USRDS Annual Data Report: epidemiology of kidney disease in the United States.

National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases;, Bethesda, MD:Kovesdy CP Park JC Kalantar-Zadeh K

Glycemic control and burnt-out diabetes in ESRD.

Semin Dial. 23: 148-156Kovesdy CP Sharma K Kalantar-Zadeh K

Glycemic control in diabetic CKD patients: where do we stand?.

Am J Kidney Dis. 52: 766-777Rhee CM Leung AM Kovesdy CP Lynch KE Brent GA Kalantar-Zadeh K

Updates on the management of diabetes in dialysis patients.

Semin Dial. 27: 135-145

Rhee CM, Kim SB, Mehrotra R, Streja E, Nguyen DV, Brunelli SM, et al. Predictors of glycemic status and associations with mortality in incident diabetic hemodialysis patients. Abstract presented at: 2015 American Society of Nephrology Kidney Week Meeting, San Diego, CA.

Rhee CM, Kim S, Mehrotra R, Gillen D, Brunelli SM, Kovesdy CP, et al. Glycated hemoglobin levels and mortality in a large US cohort of incident diabetic hemodialysis patients. Abstract presented at: 2015 European Renal Association-European Dialysis Transplantation Congress, London, UK.

Rhee CM, Ravel VA, Streja E, Soohoo M, Jing J, Nguyen DV, et al. The impact of pre-ESRD glycemic status on early post-ESRD mortality among US veterans: a transition of care in CKD study. Abstract presented at: 2015 American Society of Nephrology Kidney Week Meeting.

Rhee CM Kovesdy CP Ravel VA et al.

Association of glycemic status during progression of chronic kidney disease with early dialysis mortality in patients with diabetes.

Diabetes Care. 40: 1050-1057Moen MF Zhan M Hsu VD et al.

Frequency of hypoglycemia and its significance in chronic kidney disease.

Clin J Am Soc Nephrol. 4: 1121-1127

Kang DH, Streja E, You AS, Lee YK, Kovesdy CP, Kalantar-Zadeh K, et al. Hypoglycemia and mortality risk in incident hemodialysis patients. Abstracted presented at: 2019 American Society of Nephrology Kidney Week Meeting, Washington, DC.

Rhee CM Kovesdy CP You AS et al.

Hypoglycemia-related hospitalizations and mortality among patients with diabetes transitioning to dialysis.

Am J Kidney Dis. 72: 701-710Gerich JE Meyer C Woerle HJ Stumvoll M

Renal gluconeogenesis: its importance in human glucose homeostasis.

Diabetes Care. 24: 382-391Legouis D Faivre A Cippa PE de Seigneux S

Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism.

Nephrol Dial Transplant. ()

Haemodialysis-induced hypoglycaemia and glycaemic disarrays.

Nat Rev Nephrol. 11: 302-313Mak RH Bettinelli A Turner C Haycock GB Chantler C

The influence of hyperparathyroidism on glucose metabolism in uremia.

J Clin Endocrinol Metab. 60: 229-233Mak RH Turner C Haycock GB Chantler C

Secondary hyperparathyroidism and glucose intolerance in children with uremia.

Kidney Int Suppl. 16: S128-S133

Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients.

Kidney Int. 41: 1049-1054

1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia.

Kidney Int. 53: 1353-1357Koppe L Fouque D Soulage CO

Metabolic abnormalities in diabetes and kidney disease: role of uremic toxins.

Curr Diab Rep. 18: 97

Probiotics and chronic kidney disease.

Kidney Int. 88: 958-966McCaleb ML Izzo MS Lockwood DH

Characterization and partial purification of a factor from uremic human serum that induces insulin resistance.

J Clin Invest. 75: 391-396American Diabetes Association. 6

Glycemic targets: standards of medical care in diabetes-2020.

Diabetes Care. 43: S66-S76Diabetes C Complications Trial Research G Nathan DM et al.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

N Engl J Med. 329: 977-986United Kingdom Prospective Diabetes Study (UKPDS)

Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.

BMJ. 310: 83-88

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview.

Diabetes Care. 37: 9-16Nathan DM Cleary PA Backlund JY et al.

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

N Engl J Med. 353: 2643-2653Holman RR Paul SK Bethel MA Matthews DR Neil HA

10-year follow-up of intensive glucose control in type 2 diabetes.

N Engl J Med. 359: 1577-1589Ismail-Beigi F Craven T Banerji MA et al.

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Lancet. 376: 419-430Group AC Patel A MacMahon S et al.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

N Engl J Med. 358: 2560-2572Duckworth W Abraira C Moritz T et al.

Glucose control and vascular complications in veterans with type 2 diabetes.

N Engl J Med. 360: 129-139

KDOQI clinical practice guideline for diabetes and CKD: 2012 update.

Am J Kidney Dis. 60: 850-886Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group

KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.

Kidney Int Suppl. 3: 1-150Tuttle KR Bakris GL Bilous RW et al.

Diabetic kidney disease: a report from an ADA Consensus Conference.

Am J Kidney Dis. 64: 510-533Tuttle KR Bakris GL Bilous RW et al.

Diabetic kidney disease: a report from an ADA Consensus Conference.

Diabetes Care. 37: 2864-2883Papademetriou V Lovato L Doumas M et al.

Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes.

Kidney Int. 87: 649-659Shurraw S Hemmelgarn B Lin M et al.

Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study.

Arch Intern Med. 171: 1920-1927Limkunakul C de Boer IH Kestenbaum BR Himmelfarb J Ikizler TA Robinson-Cohen C

The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease.

J Diabetes Complications. 33: 296-301Williams ME Lacson Jr., E Wang W Lazarus JM Hakim R

Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.

Clin J Am Soc Nephrol. 5: 1595-1601Ricks J Molnar MZ Kovesdy CP et al.

Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study.

Diabetes. 61: 708-715Ramirez SP McCullough KP Thumma JR et al.

Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Diabetes Care. 35: 2527-2532Hill CJ Maxwell AP Cardwell CR et al.

Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis.

Am J Kidney Dis. 63: 84-94Kalantar-Zadeh K Kovesdy CP Streja E et al.

Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney disease.

Nephrol Dial Transplant. 32: ii91-ii98Rhee CM Kovesdy CP Ravel VA et al.

Glycemic status and mortality in chronic kidney disease according to transition versus nontransition to dialysis.

J Ren Nutr. 29: 82-90Kawahito S Kitahata H Oshita S

Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress.

World J Gastroenterol. 15: 4137-4142

Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?.

J Clin Invest. 112: 986-988

Hypoglycemia, functional brain failure, and brain death.

J Clin Invest. 117: 868-870Gosmanov AR Gosmanova EO Kovesdy CP

Evaluation and management of diabetic and non-diabetic hypoglycemia in end-stage renal disease.

Nephrol Dial Transplant. 31: 8-15Robinson RT Harris ND Ireland RH Lee S Newman C Heller SR

Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia.

Diabetes. 52: 1469-1474

The barrier of hypoglycemia in diabetes.

Diabetes. 57: 3169-3176Galindo RJ Beck RW Scioscia MF Umpierrez GE Tuttle KR

Glycemic monitoring and management in advanced chronic kidney disease.

Endocr Rev. 41: 756-774Novodvorsky P Bernjak A Chow E et al.

Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes.

Diabetes Care. 40: 655-662Suh SW Gum ET Hamby AM Chan PH Swanson RA

Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase.

J Clin Invest. 117: 910-918Yu TM Lin CL Chang SN Sung FC Kao CH

Increased risk of stroke in patients with chronic kidney disease after recurrent hypoglycemia.

Neurology. 83: 686-694